System Chief of Academic Malignant Hematology

Northwell Health Cancer Institute is seeking a visionary physician leader to serve as the inaugural System Chief of Hematologic Malignancies. This landmark role focuses on advancing and expanding hematologic oncology research programs across one of the nation's most dynamic health systems. The successful candidate will build a world-class clinical and translational research program, contributing to the Institute's mission of providing state-of-the-art, compassionate cancer care with access to cutting-edge investigational therapies.

Practice Info

• Northwell Health treats more than 24,000 patients with cancer annually.
• Provides access to over 400 Cancer Institute physicians across more than 25 subspecialties.
• The Feinstein Institute for Medical Research serves as the hub of Northwell Health's research enterprise.
• Strategic partnership with Cold Spring Harbor Laboratory accelerates translation of basic science discoveries into patient care.

Responsibilities

• Design and implement a cohesive system-wide strategy for hematologic malignancies.
• Establish disease-specific centers of excellence with dedicated multidisciplinary teams for Lymphoma, Leukemia, Multiple Myeloma, and Plasma Cell Disorders.
• Collaborate with cellular therapy and bone marrow transplant programs to create a seamless continuum of care.
• Establish and fortify a robust clinical trials infrastructure for hematologic malignancies, including early-phase (Phase I/II) investigator-initiated studies.
• Recruit and mentor physician-scientists to build translational and clinical research portfolios.
• Pursue NCI designation contributions through scholarly output, grant funding, and programmatic development.
• Develop the next generation of leaders through medical education, fellowship training, and mentorship programs.
• Partner with the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell to advance educational and academic missions.

Requirements

• MD or MD/PhD from an accredited institution.
• Board Certification in Hematology and/or Medical Oncology.
• Significant clinical expertise and national/international reputation in one or more areas of hematologic malignancies (lymphoma, leukemia, myeloma, MDS/MPNs).
• Demonstrated track record of productive clinical and translational cancer research.
• Proven success in obtaining external peer-reviewed funding.
• Eligibility for appointment at the rank of Associate Professor or Professor at the Zucker School of Medicine.
• Active or eligible for medical licensure in New York State.